Ever wish you could imagine the pandemic never happened? This is what the world of financing for biotechs looks like without it in BioCentury Chk out our FREE (with registration) financial dashboard here: biocentury.com/bciq-data/fina… Great way for you to run your own analysis!

.ARPA-H is coming into focus. The agency's first director, Renee Wegrzyn, is creating a plan to achieve things that seem impossible. Wegrzyn speaks with Washington Editor @SteveUsdin1 on the #BioCenturyShow buff.ly/3t0ydHf

Next-gen gene editing at ASH #ash2024 #ash24 Details and analysis @biocentury biocentury.com/article/650931…

What indicators are you looking at for signs of a biotech public market recovery? Post Follow-On Performance on your radars? Check out our "The Year of Biotech's Recovery" analysis here BioCentury : biocentury.com/article/651069… (trial/sub access required)

Can you guess what CAR T therapies for MM are in this graph? Details here BioCentury : biocentury.com/article/651300 (sub/trial access required)

Check out the latest episode of The BioCentury Show w/Khoo Shi, CEO of ClavystBio (Temasek). Learn: Which global investors are helping #Singapore biotechs tap into global networks and talent. Watch: youtube.com/watch?v=TjNMER… P.S. Want to learn more? BioCenturyEastWest.com

Private Radiopharma companies favor funding for β- and α-emitting Radioisotopes, exploring next-wave Targets alongside or instead of established SSTR2 and PSMA targets. Access report: #Radiopharmaceuticals’ multi-dimensional next wave: bit.ly/3UHhKTZ #radiopharmacy

Three weeks remain until #biopharma executives and investors gather in Singapore for the 3rd #BioCenturyEastWest Summit. Join us for two days of networking, partnering, and debate on how to build global #biotech ecosystems. Register: ow.ly/hbvj50QE97g

Anti-China bills portend massive blow to biotech. According to a BioCentury survey, an overwhelming majority of biotechs expect pipeline setbacks; many oppose BIO’s reversal buff.ly/4cpmAeW

Mike Gallagher's impending resignation could take some steam out of the Biosecure Act, but national security concerns about Chinese biotech isn't dissipating buff.ly/3Pz1ykb

I’ve noticed both subscribers and soon-to-be-subscribers checking out this report. DM me or reach out on our website for access. 😎 x.com/BioCentury/sta…

We enjoyed hosting journalist and author Steve Usdin for a lively discussion about his work, regulatory policies, and oncology drug development. Thank you for stopping by steve usdin!

I'm passionate about FDA advisory committees because if they're done right they're invaluable. I agree w/ this BioCentury commentary that plans to reform the process have been disappointing. biocentury.com/article/653759… Fwiw I cobbled together a few proposals. x.com/RxRegA/status/…

linkedin.com/posts/mattkreb…

linkedin.com/posts/mattkreb…